Réf. : Convergences.online/Onco ; 1 (1) : R8 Giaconne and al. Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up. J Thorac Oncol. 2021 Mar;16(3):483-485. Epub 2020 Nov 25. [...]
Réf. : Convergences.online/Onco ; 1 (1) : R7 Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021; 384: 1529–1541. Résumé [...]
Réf. : Convergences.online/Onco ; 1 (1) : R6 Kojima T, Shah MA, Muro K, et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin [...]
Réf. : Convergences.online/Onco ; 1 (1) : R5 Bahadoer RR, Dijkstra EA ,Van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, [...]
Réf. : Convergences.online/Onco ; 1 (1) : R4 Quénet F, Dominique Elias D, Lise Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal [...]
Alva AS, Mangat PK, Garrett-Mayer E, et al. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Journal [...]
Réf. : Convergences.online/Onco ; 1 (1) : U3 Pembrolizumab dans le traitement du cancer colorectal métastatique MSI Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer Contexte de l’étude L’arrivée de l’immunothérapie, et plus [...]
Kasper S, Foch C, Messinger D, et al. Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. Eur J Cancer 2021 [...]
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Zhou et al. Lancet Respir Med. 2021 Mar;9(3):305-314. [...]
Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, [...]
